-

Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.

“We deeply appreciate this vote of confidence in the Ivenix Infusion System and look forward to working with Premier members,” said Christian Hauer, executive board member and president, Fresenius Kabi MedTech. “Health systems and their nursing teams face many day-to-day challenges associated with infusion therapy. The Ivenix Infusion System is designed to improve the simplicity, intelligence and reliability of infusion pumps. We’re pleased Premier chose to make our smart infusion system available to its members.”

The Ivenix Infusion System is designed to overcome deficiencies in legacy pumps. The Ivenix patented pumping technology delivers critical medications with flow that is measured and controlled to help optimize safety. The pump operates unaffected by external conditions such as bag height, back pressure, and fluid viscosity to deliver accurate medication delivery, and it protects patients from uncontrolled flow.

The Ivenix Large-Volume Pump includes a large, smartphone-like touchscreen that allows clinicians to auto-program, review, and accept medication orders on the pump. The built-in integration engine within the Ivenix Infusion System supports secure interoperability with leading electronic medical records (EMR) systems. The Ivenix system from Fresenius Kabi also offers valuable tools to automate testing, reducing the implementation timeline and the resources needed to synchronize the drug library with the EMR formulary.

The Ivenix platform also facilitates enterprise-wide, centralized management of the entire pump fleet. This device command center allows for comprehensive oversight of the infusion pump fleet from device utilization to location awareness, proactive maintenance, user management, and remote software and security updates—without wasting valuable time hunting and gathering devices.

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global healthcare company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn (847) 220-3033
matt.kuhn@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Matt Kuhn (847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic sho...

FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi® (ustekinumab-aauz)

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab). Depending on state pharmacy laws in the U.S., an interchangeable biosimilar can be dispensed at the pharmacy as a substitute for the reference product without requiring direct approval from the prescribing heal...

CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi® (ustekinumab-aauz)

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® (ustekinumab-aauz). Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for “Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg.” Otulfi (ustekinumab-aauz) is FDA-approved for subcutaneous and intr...
Back to Newsroom